Yvette
Crachi

Business Manager

East River, New York, US

This photo highlights the reason I have such a desire to visit New York one day - a bustling and beautiful city by day and night.

photo credit: cabezadeturco

Global IP Strategy >Pharma, Biotech
& Chem IP Strategy >IP wars >Strategic Management
of IP >

Article Categories

Here you can browse our articles, and filter by category by clicking the links to the left.

2010.02.17	Satisfying the Requirements for Industrial Applicability - England & Wales Court of Appeal Provides Guidance For Biotech Inventions
2010.01.08	European Harmony on Selection Patents
2009.05.20	Thinking globally and strategically about intellectual property Generic Medicines Conference 19 May 2009, Sydney Australia
2009.04.30	Medical Devices and IP Strategy Presentation to Medical Devices Law & Policy Conference in Sydney, Australia 29 April 2009
2008.05.20	Pharmaceutical polymorphs & patent strategy Presentation to GMiA conference, Sydney 21 May 2008
2007.09.16	Pharmaceutical & Biotech Lifecycle Management (II) How does timing of 1st non-innovator patent affect the period of monopoly for a new drug? Mondaq most popular article — September 2007
2007.08.20	Big Blue Proposes New Type Of Patent Right Published on ipFrontline
2007.08.07	Novartis' Glivec battle with India - patentability of pharmaceutical extension patents Update and brief strategy analysis
2007.08.05	Australia even more patent-friendly after High Court decision IAM-Magazine, August/September 2007, Issue 25
2007.07.17	Pharmaceutical & Biotech Lifecycle Management (I) Are generic's launching earlier than ever? Mondaq most popular article — July 2007
2006.12.20	Lipitor Australia - unusual grounds invalidate Enantiomer Patent (Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC(No 2) [2006] FCA 1787
2006.12.07	IP strategy and regulatory controls - you don't have to be sued to get (generic) exclusivity in the US (Zocor returns) (Ranbaxy v Michael O Leavitt, US Court of Appeals for the District of Columbia, 14 Nov. 2006) Mondaq most popular article — December 2006
2006.10.14	Improper claim dependency invalidates US Lipitor patent Journal of Intellectual Property Law and Practice, Oxford University Press, 2006, 1(12): 748
2006.08.16	US Court of Appeal invalidates Lipitor patent due to improper claim dependency (Pfizer Inc. v Ranbaxy Laboratories CAFC 06-1179 (2006))
2006.07.26	Pharmaceutical taste trade marks - a bitter pill to swallow Strategic points from the US Appeals Board - In re N.V. Organon
2006.07.13	US product by process patents - Court of Appeal refuses en banc rehearing of SmithKline v Apotex
2006.07.10	The global Lipitor patent battle
2006.06.23	Pharmaceutical IP Strategy in the US - Merck’s latest tactic for Zocor
2006.06.19	Fosamax once weekly patent invalid on appeal in Australian Full Federal Court
2006.06.02	Spanish Appellate Court applies Bolar while denying interim injunction in Finasteride decision Merck Sharp & Dohme DE Espana S.A. v Bexal Farmaceutica, S.A; Provincial High Court of Madrid (00089/2006)
2006.05.29	Zocor Generic Exclusivity dispute continues on appeal in the US
2006.05.22	Experts and skilled addressee come to the fore in UK Patents Court Eloxatin decision Mayne Pharma v Debiopharm SA & Sanofi-Synthélabo [2006] EWHC 1123 (Pat)
2006.05.17	European Court of Justice rules SPCs not available for certain combination products
2006.04.13	US CAFC upholds Aventis Lovenox (enoxaparin) patent enforceability (Aventis Pharma SA v Amphastar Pharmaceuticals [2006] CAFC - 10 April 2006)
2006.04.11	Broad claim scope invalidates UK Nicorandil formulation patent despite ‘powerful arguments’ to the contrary Journal of Intellectual Property Law and Practice, Oxford University Press, 2006, Volume 1, Number 8, p 502
2006.03.30	Spring-boarding to catch up with the rest of the world: